Abbott Laboratories

Abbott Laboratories

ABT·NYSE

$87.02

-0.82%
HealthcareMedical - Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

At a Glance

Live Snapshot
Market Cap$151.57B
EPS3.7400
P/E Ratio23.27
Earnings Date07/16/2026
3Y+2.0%
5Y+28.0%
10Y+113.0%
3Y-6.0%
5Y+45.0%
10Y+366.0%
3Y-
5Y+21.0%
10Y+199.0%
Abbott Laboratories

Abbott Laboratories Profit Bridge

ABT · NYSE
Revenue44.33B
Cost of Goods Sold (19.72B)
Gross Profit24.61B
Operating Expenses (16.59B)
Operating Income8.05B
Interest Expense (341.00M)
Other Income/Expense418.00M
Pretax Income8.47B
Income Tax (1.94B)
Net Income6.52B
Net Income
6.52B

Profitability Analysis

Gross Margin

55.5%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

18.2%

Healthy operating margins demonstrate effective cost control and strong business fundamentals.

Net Profit Margin

14.7%

Strong net margins indicate efficient operations and favorable tax/interest management.

Effective Tax Rate

22.9%

Moderate tax rate typical for most corporations. Represents standard tax burden on profits.

Profitability Insight

High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.

Abbott Laboratories Income Statement

ABT • NYSE

Abbott Laboratories Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
44.3B
42B
40.1B
43.7B
43.1B
34.6B
31.9B
30.6B
27.4B
20.9B
20.4B
20.2B
21.8B
39.9B
38.9B
35.2B
30.8B
29.5B
25.9B
22.5B
GROSS PROFIT
(19.7B)
(20.6B)
(20.1B)
(21.3B)
(19.9B)
(17.2B)
(15.2B)
(14.8B)
(14.3B)
(9.6B)
(9.4B)
(9.8B)
(9.8B)
(10.6B)
(15.4B)
(14.6B)
(13.1B)
(12.5B)
(11.3B)
(9.6B)
24.6B
21.3B
20B
22.3B
23.2B
17.4B
16.7B
15.8B
13.1B
11.2B
11B
10.5B
9.9B
10.9B
23.4B
20.6B
17.6B
17B
14.6B
12.8B
OPERATING INCOME
(16.6B)
(14.5B)
(13.6B)
(14B)
(14B)
(12.1B)
(12.1B)
(12B)
(11.1B)
(8B)
(8B)
(7.6B)
(7.7B)
(8.8B)
(16.6B)
(13.5B)
(11B)
(11B)
(9.6B)
(8.5B)
(12.4B)
(11.7B)
(10.9B)
(11.1B)
(11.3B)
(9.7B)
(9.7B)
(9.7B)
(9B)
(6.6B)
(6.6B)
(6.3B)
(6.3B)
(7.3B)
(12.5B)
(10B)
(8.3B)
(8.3B)
(7.2B)
(6.3B)
(3B)
(2.8B)
(2.7B)
(2.9B)
(2.7B)
(2.4B)
(2.4B)
(2.3B)
(2.1B)
(1.4B)
(1.4B)
(1.3B)
(1.4B)
(1.5B)
(4.1B)
(3.6B)
(2.7B)
(2.7B)
(2.4B)
(2.2B)
8B
6.8B
6.4B
8.4B
9.2B
5.3B
4.6B
3.8B
2B
3.2B
2.9B
2.9B
2.1B
2B
6.8B
7.1B
6.6B
6.1B
4.9B
4.3B
PRE-TAX INCOME
(341M)
(603M)
(698M)
(315M)
(410M)
(708M)
(818M)
(729M)
(880M)
(304M)
(178M)
(164M)
(47M)
(409M)
(1B)
(801.1M)
(210.7M)
(528.5M)
(593.1M)
(416.2M)
-111M
-259M
-313M
-132M
-367M
-662M
-724M
-624M
-756M
-205M
-73M
-87M
20M
-350M
-932.9M
-695.7M
-72.9M
-327.2M
-456.4M
-292.3M
(1.3B)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
418M
188M
229M
-56M
-989M
-323M
-514M
-971M
259M
-1.8B
234M
-398M
-105M
-1.7B
-1.6B
-1.3B
623M
-232.8M
-475.9M
-2.1B
8.5B
7B
6.7B
8.3B
8.2B
5B
4.1B
2.9B
2.2B
1.4B
3.2B
2.5B
2.5B
6.3B
5.2B
5.7B
7.2B
5.9B
4.5B
2.3B
NET INCOME
(1.9B)
-6.4B
(941M)
(1.4B)
(1.1B)
(497M)
(390M)
(539M)
(1.9B)
(350M)
(577M)
(797M)
(138M)
(300M)
(470M)
(1.1B)
(1.4B)
(1.1B)
(863.3M)
(559.6M)
6.5B
13.4B
5.7B
6.9B
7.1B
4.5B
3.7B
2.4B
477M
1.4B
4.4B
2.3B
2.6B
6B
4.7B
4.6B
5.7B
4.9B
3.6B
1.7B

SEC Filings

ABT - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

April 29, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 27, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

April 17, 2026
April 10, 2026
2026
8-K

8-K 2026

N/A

April 16, 2026
April 16, 2026
2026
8-K

8-K 2026

N/A

March 23, 2026
March 23, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 13, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

March 09, 2026
March 09, 2026
2026
8-K

8-K 2026

N/A

February 26, 2026
February 23, 2026
2026
10-K

10-K 2025 FY

FY

February 20, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 20, 2026
February 20, 2026
2026
Showing 1 to 10 of 484 filings